{
    "name": "decitabine",
    "comment": "Rx",
    "other_names": [
        "Dacogen"
    ],
    "classes": [
        "Antineoplastics",
        "DNA Methylation Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/dacogen-decitabine-342091",
    "pregnancy": {
        "common": [
            "Based on findings from human data, animal studies, and the mechanism of action, therapy can cause fetal harm when administered to a pregnant woman; limited published data on use throughout first trimester during pregnancy describe adverse developmental outcomes including major birth defects (structural abnormalities); advise pregnant women of potential risk to fetus",
            "Based on findings of decitabine in animals, male fertility may be compromised by treatment; reversibility of effect on fertility is unknown",
            "Conduct pregnancy testing of females of reproductive potential prior to initiating treatment",
            "Advise females of reproductive potential to avoid pregnancy and use effective contraception while receiving therapy and for 6 months following last dose",
            "Advise males with female partners of reproductive potential to use effective contraception while receiving treatment and for 3 months following last dose"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, administration of decitabine to pregnant mice and rats during organogenesis caused adverse developmental outcomes and was teratogenic, fetotoxic, and embryotoxic starting at doses approximately 7% of the recommended human dose on a mg/m2 basis"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug or metabolites in human milk, effects on breastfed child, or on milk production; because many drugs are excreted in human milk, and because of potential for serious adverse reactions in a nursing child, advise lactating women to avoid breastfeeding during treatment and for at least 1 week after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in renal/hepatic impairment",
                "Fatal and serious myelosuppression occurs in treated patients; myelosuppression (anemia, neutropenia, and thrombocytopenia) is the most frequent cause of dose reduction, delay, and discontinuation; manage toxicity using dose-delay, dose-reduction, growth factors, and anti-infective therapies as needed; myelosuppression and worsening neutropenia may occur more frequently in first or second treatment cycles, and may not necessarily indicate progression of underlying MDS",
                "Therapy can cause fetal harm when administered to a pregnant woman; based on mechanism of action, drug alters DNA synthesis and is expected to result in adverse reproductive effects; advise men with female partners of childbearing potential to avoid fathering a child while receiving treatment and for 3 months following the last dose; counsel patients of childbearing potential to use effective contraception during this time",
                "Bone marrow suppression may occur (dose limiting); dose adjustment may be necessary"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of decitabine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, decitabine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, decitabine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "decitabine decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "decitabine decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and decitabine both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "decitabine increases levels of ethotoin by unknown mechanism. Use Caution/Monitor. Based on case reports."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "decitabine increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "decitabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and decitabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and decitabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "decitabine decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of decitabine by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "taurine",
            "description": {
                "common": "decitabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin A",
            "description": {
                "common": "vitamin A, decitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin E",
            "description": {
                "common": "vitamin E, decitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Neutropenia",
            "percent": "90"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "89"
        },
        {
            "name": "Anemia",
            "percent": "82"
        },
        {
            "name": "Pyrexia",
            "percent": "53"
        },
        {
            "name": "Nausea",
            "percent": "42"
        },
        {
            "name": "Cough",
            "percent": "40"
        },
        {
            "name": "Petechiae",
            "percent": "39"
        },
        {
            "name": "Constipation",
            "percent": "35"
        },
        {
            "name": "Diarrhea",
            "percent": "34"
        },
        {
            "name": "Hyperglycemia",
            "percent": "33"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "29"
        },
        {
            "name": "Headache",
            "percent": "28"
        },
        {
            "name": "Insomnia",
            "percent": "28"
        },
        {
            "name": "Leukopenia",
            "percent": "28"
        },
        {
            "name": "Vomiting",
            "percent": "25"
        },
        {
            "name": "Peripheral edema",
            "percent": "25"
        },
        {
            "name": "Hypoalbuminemia",
            "percent": "24"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "24"
        },
        {
            "name": "Pallor",
            "percent": "23"
        },
        {
            "name": "Hypokalemia",
            "percent": "22"
        },
        {
            "name": "Pneumonia",
            "percent": "22"
        },
        {
            "name": "Rigors",
            "percent": "22"
        },
        {
            "name": "Ecchymosis",
            "percent": "22"
        },
        {
            "name": "Arthralgia",
            "percent": "20"
        },
        {
            "name": "Limb pain",
            "percent": "19"
        },
        {
            "name": "Hyponatremia",
            "percent": "19"
        },
        {
            "name": "Rash",
            "percent": "19"
        },
        {
            "name": "Edema",
            "percent": "18"
        },
        {
            "name": "Dizziness",
            "percent": "18"
        },
        {
            "name": "Back pain",
            "percent": "17"
        },
        {
            "name": "Appetite decreased",
            "percent": "16"
        },
        {
            "name": "Pharyngitis",
            "percent": "16"
        },
        {
            "name": "Cardiac murmur",
            "percent": "16"
        },
        {
            "name": "Anorexia",
            "percent": "16"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "14"
        },
        {
            "name": "Abdominal pain",
            "percent": "14"
        },
        {
            "name": "Erythema",
            "percent": "14"
        },
        {
            "name": "Crackles in lung",
            "percent": "14"
        },
        {
            "name": "Oral mucosal petechiae",
            "percent": "13"
        },
        {
            "name": "Pain",
            "percent": "13"
        },
        {
            "name": "Hyperkalemia",
            "percent": "13"
        },
        {
            "name": "Confusional state",
            "percent": "12"
        },
        {
            "name": "Lethargy",
            "percent": "12"
        },
        {
            "name": "Stomatitis",
            "percent": "12"
        },
        {
            "name": "Dyspepsia",
            "percent": "12"
        },
        {
            "name": "Lymphadenopathy",
            "percent": "12"
        },
        {
            "name": "Cellulitis",
            "percent": "12"
        },
        {
            "name": "Anxiety",
            "percent": "11"
        },
        {
            "name": "Hypoesthesia",
            "percent": "11"
        },
        {
            "name": "Tenderness",
            "percent": "11"
        },
        {
            "name": "Blood alkaline phosphatase increased",
            "percent": "11"
        },
        {
            "name": "Skin lesion",
            "percent": "11"
        },
        {
            "name": "Pruritus",
            "percent": "11"
        },
        {
            "name": "Aspartate aminotransferase increase",
            "percent": "10"
        },
        {
            "name": "Blood urea increase",
            "percent": "10"
        },
        {
            "name": "Breath sounds decrease",
            "percent": "10"
        },
        {
            "name": "Hypoxia",
            "percent": "10"
        },
        {
            "name": "Candidal infection",
            "percent": "10"
        },
        {
            "name": "Ascites",
            "percent": "10"
        },
        {
            "name": "Blood lactate dehydrogenase increase",
            "percent": "8"
        },
        {
            "name": "Catheter related infection",
            "percent": "8"
        },
        {
            "name": "Gingival bleeding",
            "percent": "8"
        },
        {
            "name": "Hemorrhoids",
            "percent": "8"
        },
        {
            "name": "Alopecia",
            "percent": "8"
        },
        {
            "name": "Fall",
            "percent": "8"
        },
        {
            "name": "Rales",
            "percent": "8"
        },
        {
            "name": "Loose stools",
            "percent": "7"
        },
        {
            "name": "Transfusion reaction",
            "percent": "7"
        },
        {
            "name": "Tongue ulceration",
            "percent": "7"
        },
        {
            "name": "Chest discomfort",
            "percent": "7"
        },
        {
            "name": "Chest wall pain",
            "percent": "7"
        },
        {
            "name": "Blood albumin decrease",
            "percent": "7"
        },
        {
            "name": "Urinary tract infection",
            "percent": "7"
        },
        {
            "name": "Staphylococcal infection",
            "percent": "7"
        },
        {
            "name": "Oral candidiasis",
            "percent": "6"
        },
        {
            "name": "Dysuria",
            "percent": "6"
        },
        {
            "name": "Dysphagia",
            "percent": "6"
        },
        {
            "name": "Pulmonary edema",
            "percent": "6"
        },
        {
            "name": "Blurred vision",
            "percent": "6"
        },
        {
            "name": "Oral soft tissue disorder",
            "percent": "6"
        },
        {
            "name": "Urticaria",
            "percent": "6"
        },
        {
            "name": "Swelling of face",
            "percent": "6"
        },
        {
            "name": "Blood Cl decrease",
            "percent": "6"
        },
        {
            "name": "Blood bicarbonate increase",
            "percent": "6"
        },
        {
            "name": "Musculoskeletal discomfort",
            "percent": "6"
        },
        {
            "name": "Hypotension",
            "percent": "6"
        },
        {
            "name": "Dehydration",
            "percent": "6"
        },
        {
            "name": "Intermittent pyrexia",
            "percent": "6"
        },
        {
            "name": "Lip ulceration",
            "percent": "5"
        },
        {
            "name": "Thrombocythemia",
            "percent": "5"
        },
        {
            "name": "Hematoma",
            "percent": "5"
        },
        {
            "name": "Abdominal distension",
            "percent": "5"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "5"
        },
        {
            "name": "Gastro",
            "percent": "5"
        },
        {
            "name": "esophageal reflux disease",
            "percent": "5"
        },
        {
            "name": "Glossodynia",
            "percent": "5"
        },
        {
            "name": "Myalgia",
            "percent": "5"
        },
        {
            "name": "Malaise",
            "percent": "5"
        },
        {
            "name": "Crepitations",
            "percent": "5"
        },
        {
            "name": "Catheter site erythema",
            "percent": "5"
        },
        {
            "name": "Catheter site pain",
            "percent": "5"
        },
        {
            "name": "Injection site swelling",
            "percent": "5"
        },
        {
            "name": "Urinary frequency",
            "percent": "5"
        },
        {
            "name": "Sinusitis",
            "percent": "5"
        },
        {
            "name": "Postnasal drip",
            "percent": "5"
        },
        {
            "name": "Bacteremia",
            "percent": "5"
        },
        {
            "name": "Abrasion",
            "percent": "5"
        },
        {
            "name": "Protein total decrease",
            "percent": "5"
        },
        {
            "name": "Blood bicarbonate decrease",
            "percent": "5"
        },
        {
            "name": "Blood bilirubin decreased",
            "percent": null
        },
        {
            "name": "Sweet",
            "percent": null
        },
        {
            "name": "s syndrome",
            "percent": null
        },
        {
            "name": "acute febrile neutrophilic dermatosis",
            "percent": null
        },
        {
            "name": "Differentiation syndrome",
            "percent": null
        },
        {
            "name": "Interstitial lung disease",
            "percent": null
        }
    ]
}